Rendong Medicine and Huizheng Pharma Launch Commercial Partnership for Breast Cancer Precision Diagnosis and Treatment Product Portfolio
[October 31, 2020, Shanghai] The exclusive commercial agency agreement between Huizheng (Shanghai) Pharmaceutical Technology Co., Ltd. (“Huizheng Pharma”), a wholly-owned subsidiary of Hansoh Pharmaceutical Group Co., Ltd., and Rendong Medical Technology Co., Ltd. (“Rendong Medical”), regarding the series of precision diagnosis and treatment products for breast cancer in mainland China, has officially come into effect. Under this agreement, Huizheng Pharma will provide market promotion and marketing services for Rendong Medical’s product portfolio.
Rendong Medicine is China’s leading provider of comprehensive genetic testing solutions and the market leader in precision diagnostics for urological tumors in China. It is extending its mature R&D and clinical translation model to additional oncology areas, including breast cancer. Huizheng Pharmaceutical is a leading pharmaceutical company in the Chinese market, dedicated to developing, manufacturing, and promoting original drugs and international-standard branded generics for both China and global markets. Its portfolio covers numerous therapeutic areas, including oncology, anti-infectives, cardiovascular diseases, diabetes, hormones, and immunosuppressants, supported by a cGMP-compliant quality system.
Upholding the philosophy of “practicing precision medicine and safeguarding healthy lives,” RenDong Medicine has developed a series of products for the precise diagnosis and treatment of breast cancer. The aim is to establish an individualized, comprehensive diagnostic and therapeutic system for breast cancer based on standardized treatment protocols, patient genetic information, and evidence-based medicine, thereby providing references for clinical management and genetic risk assessment. In China, breast cancer is the most prevalent malignancy among women, with approximately 300,000 new cases diagnosed annually. This collaboration leverages the respective strengths of Huizheng Pharmaceutical and RenDong Medicine, focusing on the field of precision diagnosis and treatment of breast cancer, to jointly build an integrated diagnostic and therapeutic solution for Chinese patients with breast cancer.
1. Personalized medication selection and comprehensive management of the entire diagnosis and treatment process for patients with all types of breast cancer;
2. Prognostic assessment and evaluation of adjuvant chemotherapy benefits in patients with early-stage hormone receptor-positive breast cancer;
3. Hereditary cancer risk assessment for patients with a family history of cancer or healthy individuals.
Rendong Medicine, established in December 2015, is a leading provider of comprehensive genetic testing solutions in China and the market leader in genetic testing for urological tumors. Centered on next-generation sequencing (NGS) technology and leveraging tumor immuno-multi-omics, the company focuses on building integrated diagnostic and therapeutic solutions for specific cancer types. In 2017, it pioneered the “Ten-Thousand Patient Tumor Immune Ark Project” in China and launched the country’s first ctDNA panel for precise immuno-oncology therapy and efficacy assessment. Its product portfolio now covers the entire continuum of precision oncology, including precise immunotherapy, medication guidance, and prognosis prevention. Notably, its flagship products—Pushengtai® (a 66-gene assay for precise diagnosis and treatment of prostate cancer), Youke’an™ (a genetic testing product for precise diagnosis and treatment of urothelial carcinoma), and Shenshi’an Selected™ (a 77-gene assay for precise diagnosis and treatment of renal cell carcinoma)—have become well-known brands in their respective niche indications. Additionally, the company has relevant products and R&D initiatives in breast cancer, colorectal cancer, head and neck squamous cell carcinoma, and other tumor types. Rendong Medicine has commenced construction of an IVD manufacturing facility and new office spaces in Suzhou, and successfully secured strategic Series A and Pre-Series B financing from the capital markets in 2018 and 2020, respectively.
Hanhui Pharmaceutical Co., Ltd. was renamed from the former leading domestic pharmaceutical enterprise, Hisun Pfizer Pharmaceuticals Co., Ltd. Since its establishment, Hanhui Pharmaceutical has always adhered to the corporate philosophy of “Patients First, Quality as the Foundation; Innovation and Change, Pursuit of Excellence; Integrity and Compliance, Growth and Win-Win,” and is committed to exploring and providing the highest quality medicines and disease solutions. In the future, Hanhui Pharmaceutical will develop, produce, and promote high-quality, affordably priced originator drugs and brand-name generics that meet international standards for both the Chinese and global markets, while inheriting and continuing the quality and compliance requirements of the former Pfizer system. Hanhui has formed long-term strategic partnerships with many well-known pharmaceutical companies at home and abroad in multiple fields such as anti-infection, cardiovascular and cerebrovascular diseases, diabetes, and oncology. Hanhui Pharmaceutical is a leading domestic pharmaceutical company that provides a full industry chain service system including registration, importation, distribution, and promotion of pharmaceuticals and medical devices, possesses a production platform compliant with FDA certification, and has a marketing network covering all provinces and cities across China. Hanhui Pharmaceutical is one of the top 40 pharmaceutical companies in China by revenue, achieving a revenue of RMB 4.299 billion in 2019.